Captopril and Trandolapril — Competitive Intelligence Brief

Captopril and Trandolapril (Captopril and Trandolapril) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

marketed ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule

Target snapshot

Captopril and Trandolapril (Captopril and Trandolapril) — Rigshospitalet, Denmark. Both captopril and trandolapril inhibit angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Captopril and Trandolapril TARGET	Captopril and Trandolapril	Rigshospitalet, Denmark	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Vasotec	enalapril	Merck & Co.	marketed	ACE inhibitor	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1985-12-24
ACEI/DIU	ACEI/DIU	Shanghai Jiao Tong University School of Medicine	marketed	ACE inhibitor/Diuretic combination	Angiotensin-converting enzyme (ACE)
Atorvastatin, Amlodipine, Perindopril	Atorvastatin, Amlodipine, Perindopril	Charles University, Czech Republic	marketed	Fixed-dose combination: statin, calcium channel blocker, ACE inhibitor	HMG-CoA reductase (atorvastatin); L-type calcium channels (amlodipine); Angiotensin-converting enzyme (perindopril)
Aliskiren, Perindopril	Aliskiren, Perindopril	Medical University of Gdansk	marketed	Antihypertensive combination (direct renin inhibitor + ACE inhibitor)	Renin and Angiotensin-Converting Enzyme (ACE)
angiotensin blockade	angiotensin blockade	The University of Hong Kong	marketed	Angiotensin receptor blocker (ARB) or ACE inhibitor	Angiotensin II type 1 receptor (AT1R) or Angiotensin-converting enzyme (ACE)
ACE Reno	ACE Reno	Ace Cells Lab Limited	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

1. Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
2. Bioprojet · 2 drugs in this class
3. Ain Shams University · 2 drugs in this class
4. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
5. Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
6. Children's Hospital of Fudan University · 1 drug in this class
7. Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Ethicare GmbH · 1 drug in this class
10. Ace Cells Lab Limited · 1 drug in this class